N
Neurelis
Specialty pharmaceutical firm that licenses, develops, and commercializes product candidates for epilepsy and the cns market
About Neurelis
Neurelis, Inc. is a neuroscience-based pharmaceutical company focused on delivering innovative therapies designed to address unmet medical needs. The company operates in the pharmaceutical and biotechnology market, serving patients and healthcare professionals (HCPs) with a range of proprietary technologies aimed at enhancing drug delivery and stabilization. Neurelis' business model revolves around the development and commercialization of novel therapeutic solutions, leveraging its proprietary non-invasive drug delivery technologies to improve clinical outcomes and patient care. The company generates revenue through the sale of its pharmaceutical products and through partnerships and collaborations with other entities in the healthcare sector. Neurelis is committed to advancing its pipeline of investigational product candidates, which are at various stages of development, to bring new and effective treatments to market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- San Diego, United States
- Employees
- 187
- Open positions
- 8
- Dealroom signal
- 72.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Epilepsy, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2018
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Aug 2021 | $150M | — | OrbiMed | — |
| SERIES DOther financing | Mar 2021 | $114M | $456M | LYZZ Capital · Philos & Partners · Decheng Capital · Cormorant Asset Management | — |
Growth signals
Latest recorded traffic for Neurelis is 6.9K monthly website visits, up 53.3% over the last three months. Neurelis's team grew 6.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- LCLYZZ Capital
HBM Healthcare Investments
Series B and later4 investors entered at this stage
- PPPhilos & Partners
Decheng Capital
Cormorant Asset Management
OrbiMed
Other known investors1 additional known investor
Biotie Therapies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurelis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurelis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.